Definium Therapeutics Insider Purchases: Matthew Wiley Buys 62,500 Shares

On June 22, 2026, Matthew Wiley, the Chief Commercial Officer of Definium Therapeutics, Inc. (NasdaqGS: DFTX), purchased 62,500 shares of the company. This insider transaction highlights the confidence of the company's management team in its future prospects.

Insider Buying and Selling at Definium Therapeutics, Inc.

Matthew Wiley wasn't the only insider making moves in Definium Therapeutics recently. On the same day, several other top executives also purchased shares. Chief Medical Officer Daniel Karlin bought 100,000 shares, Chief Legal Officer Mark Sullivan and Chief Financial Officer Brandi Roberts each acquired 62,500 shares, and CEO Robert Barrow purchased 375,000 shares. None of these transactions were part of a pre-planned trading program.

Other Institutional Activity in Definium Therapeutics

Several institutional investors also showed interest in Definium Therapeutics. BlackRock, Inc. opened a new position with 8,480,230 shares worth about $160.3 million. Driehaus Capital Management LLC trimmed its holdings by 625,313 shares, reducing its stake by 9.6% to 5,911,889 shares valued at approximately $111.7 million. Avoro Capital Advisors LLC and Janus Henderson Group PLC both initiated new positions, with Avoro acquiring 5,000,000 shares valued at $94.5 million and Janus Henderson securing 3,556,041 shares worth $67.2 million. Geode Capital Management, LLC also entered with 2,495,399 shares valued at $47.2 million.

Definium Therapeutics, Inc. Stock Down 10.5%

Shares of Definium Therapeutics traded near $24.48 on Monday. The company, which operates in the biotech sector, has a market capitalization of approximately $2.67 billion. It currently has no meaningful forward P/E ratio due to its lack of profitability. The stock's beta is 2.378, indicating higher volatility compared to the market. Over the past 52 weeks, the stock has ranged from $6.35 to $26.25. The 50-day moving average is $22.61, while the 200-day moving average stands at $16.28.

Analysts Set New Price Targets

Analysts have shown optimism about Definium's potential. On June 16, 2026, Canaccord Genuity maintained its 'buy' rating with a price target of $38. Piper Sandler, on May 8, 2026, also maintained a 'buy' rating, setting its target at $48. Leerink Partners and Stifel both initiated coverage with 'buy' ratings, targeting $30 each. Overall, the consensus among 15 analysts is a 'strong buy,' with an average target price of $39.87.

About Definium Therapeutics

Definium Therapeutics, Inc. is a biopharmaceutical company based in New York, NY, focusing on developing innovative treatments for brain health disorders. Led by CEO Robert Barrow, the company is working on several promising drug candidates. Its lead products include DT120, in phase 3 trials for anxiety and depression, and DT402, in phase 2a trials for autism spectrum disorder. The company was previously known as Mind Medicine (MindMed) Inc. until its name change in January 2026.

Bottom Line

Matthew Wiley's recent purchase of 62,500 shares underscores the confidence of Definium Therapeutics' management in the company's future. Investors often watch insider transactions like these as potential indicators of a company's prospects. Keep in mind that these are backward-looking reports, reflecting insider activity as of the transaction date.